Nissinen R - Search Results

1

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis.

Mälkönen T, Nuutinen P, Hallinen T, Soini E, Nissinen R, Wennerstöm C, Rantanen T, Hagman JH, Harvima R, Höök-Nikanne J, Ilves T, Lintu P, Malanin K, Soramäki I, Tasanen K, Teho A, Vähävihu K, Itälinna S, Leinonen P, Sarajärvi P, Huilaja L, Pasternack R. Mälkönen T, et al. Among authors: nissinen r. Acta Derm Venereol. 2022 Jan 18;102:adv00631. doi: 10.2340/actadv.v101.910. Acta Derm Venereol. 2022. PMID: 34904684 Free PMC article.

2

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort.

Af Björkesten CG, Ilus T, Hallinen T, Soini E, Eberl A, Hakala K, Heikura M, Jussila A, Koskela R, Koskinen I, Moilanen V, Nielsen C, Nieminen U, Nuutinen H, Heikkinen M, Suhonen UM, Tillonen J, Utriainen K, Vihriälä I, Wennerström C, Borsi A, Nissinen R, Koivunen MR, Sipponen T. Af Björkesten CG, et al. Among authors: nissinen r. Eur J Gastroenterol Hepatol. 2020 Dec;32(12):1507-1513. doi: 10.1097/MEG.0000000000001831. Eur J Gastroenterol Hepatol. 2020. PMID: 32868649 Free PMC article.

3

Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study.

Af Björkesten CG, Jussila A, Kemppainen H, Hallinen T, Soini E, Mankinen P, Valgarðsson S, Veckman V, Nissinen R, Naessens D, Molander P. Af Björkesten CG, et al. Among authors: nissinen r. Scand J Gastroenterol. 2019 Oct;54(10):1226-1232. doi: 10.1080/00365521.2019.1667426. Epub 2019 Sep 18. Scand J Gastroenterol. 2019. PMID: 31532265

4

Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).

Eberl A, Hallinen T, Af Björkesten CG, Heikkinen M, Hirsi E, Kellokumpu M, Koskinen I, Moilanen V, Nielsen C, Nuutinen H, Suhonen UM, Utriainen K, Vihriälä I, Soini E, Wennerström C, Nissinen R, Borsi A, Koivunen M, Tillonen J, Sipponen T. Eberl A, et al. Among authors: nissinen r. Scand J Gastroenterol. 2019 Jun;54(6):718-725. doi: 10.1080/00365521.2019.1624817. Epub 2019 Jun 11. Scand J Gastroenterol. 2019. PMID: 31184512

5

Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.

Kuuliala A, Nissinen R, Kautiainen H, Repo H, Leirisalo-Repo M. Kuuliala A, et al. Among authors: nissinen r. Ann Rheum Dis. 2006 Jan;65(1):26-9. doi: 10.1136/ard.2004.034728. Epub 2005 Jun 7. Ann Rheum Dis. 2006. PMID: 15941839 Free PMC article.

6

Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.

Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. Lichtenstein GR, et al. Among authors: nissinen r. Am J Gastroenterol. 2018 Nov;113(11):1678-1688. doi: 10.1038/s41395-018-0202-9. Epub 2018 Jul 19. Am J Gastroenterol. 2018. PMID: 30022113

7

Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.

Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O. Nissinen R, et al. Ann Rheum Dis. 2004 Jun;63(6):681-7. doi: 10.1136/ard.2003.008599. Ann Rheum Dis. 2004. PMID: 15140775 Free PMC article.

8

Immune activation in the small intestine in patients with rheumatoid arthritis.

Nissinen R, Leirisalo-Repo M, Nieminen AM, Halme L, Färkkilä M, Palosuo T, Vaarala O. Nissinen R, et al. Ann Rheum Dis. 2004 Oct;63(10):1327-30. doi: 10.1136/ard.2003.011304. Ann Rheum Dis. 2004. PMID: 15361394 Free PMC article.

9

CCR3, CCR5, interleukin 4, and interferon-gamma expression on synovial and peripheral T cells and monocytes in patients with rheumatoid arthritis.

Nissinen R, Leirisalo-Repo M, Tiittanen M, Julkunen H, Hirvonen H, Palosuo T, Vaarala O. Nissinen R, et al. J Rheumatol. 2003 Sep;30(9):1928-34. J Rheumatol. 2003. PMID: 12966592

10

Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren syndrome.

Nissinen R, Paimela L, Julkunen H, Tienari PJ, Leirisalo-Repo M, Palosuo T, Vaarala O. Nissinen R, et al. Scand J Rheumatol. 2003;32(6):337-42. doi: 10.1080/03009740410004990. Scand J Rheumatol. 2003. PMID: 15080264

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page